NCT06226857View on ClinicalTrials.gov

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

355

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Colorectal NeoplasmsChemotherapy EffectMolecular Sequence Variation
Interventions
DRUG

Cetuximab

FOLFOX+cetuximab/panitumumab q2w until desease progression, deescalation to de Gramont+cetuximab/panitumumab is allowed after 8 cycles

Trial Locations (3)

108814

RECRUITING

Moscow Multidiciplinary Clinical Center Kommunarka, Moscow

115478

RECRUITING

N.N Blokhin Cancer Reserch Center, Moscow

143964

RECRUITING

Reutov Clinical hospital, Reutov

Sponsors

Collaborators (1)

Atlas Biomed
All Listed Sponsors
collaborator

Atlas Biomed

INDUSTRY

collaborator

N.N. Blokhin National Medical Research Center of Oncology

OTHER

collaborator

Moscow MultidisciplinaryClinical Center Kommunarka

UNKNOWN

lead

City Clinical Oncology Hospital No 1

OTHER_GOV

NCT06226857 - Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter